Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New RSV guideline aims to standardize pediatric care across China

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

20 Jun 2025

How Fluidics is Powering Modern Healthcare and Medical Device Innovation

The future of fluidics in healthcare: Blake Webb shares trends in automation and microfluidics that are reshaping medical diagnostics and laboratory processes.

From Fluid Metering, Inc. 12 Jun 2025

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN).

5 Jun 2025

Avelumab and cetuximab combination shows promise in phase II skin cancer trial

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC).

1 Jun 2025

Combination treatment extends progression-free survival in advanced skin cancer

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

1 Jun 2025

WHO releases first-ever position paper on immunization products to protect infants against RSV

Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect infants against respiratory syncytial virus (RSV) – the leading cause of acute lower respiratory infections in children globally.

30 May 2025

Early allergen introduction reduces childhood food allergy risk

Investigating allergy prevention, this research highlights early intervention strategies and the promise of biologic treatments in managing allergic conditions.

29 May 2025

Maternal RSV vaccine and nirsevimab sharply cut infant hospitalizations, new data show

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction in RSV-associated hospitalizations among infants aged 0–7 months. The largest benefits were seen in the youngest and most vulnerable infants, particularly during peak winter months.

20 May 2025

UArizona researchers uncover new way to ease postoperative pain in women

University of Arizona Health Sciences researchers identified a potential way to reduce female post-operative pain by inhibiting pituitary prolactin generated by pre-operative stress.

20 May 2025

CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea

CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea.

20 May 2025

Physical function before treatment predicts response to daratumumab in multiple myeloma

How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti- multiple myeloma (MM) drug, according to a new study published in the European Journal of Haematology.

14 May 2025

Nirsevimab slashes RSV hospitalizations in infants by 78% in real-world study

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe symptoms linked to RSV and other respiratory viruses. Hospitalizations for RSV dropped by 78% following nirsevimab rollout in Madrid maternity wards.

8 May 2025

Monoclonal antibody protects mice from lethal influenza A doses

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

8 May 2025

Clinical trial underway to assess effectiveness and safety of potential Long Covid treatment

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.

1 May 2025

Children with chronic conditions face higher RSV hospitalization risk

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

25 Apr 2025

Monoclonal antibody can effectively reverse bleeding complications linked to ticagrelor

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic bleeding complications linked to ticagrelor, a common drug used to treat patients with acute coronary syndromes, prior heart attack, stroke, and coronary artery disease.

24 Apr 2025

New approach targets cell surface protein to treat leukemia and solid tumors

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

23 Apr 2025

Insights into Raman spectroscopy as a bioprocess analytical technique

Dr. Nimesh Khadka discusses Raman spectroscopy's role in bioprocess monitoring, highlighting its advantages in molecular specificity and real-time analysis.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 23 Apr 2025

COVID-19 treatments show minimal serious side effects

Numerous treatment options for COVID-19 have been approved by the U.S. Food and Drug Administration over the last four years, including antiviral drugs and monoclonal antibodies that suppress an excessive immune response.

11 Apr 2025

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves neuron health in animal models of Alzheimer's disease, according to a new Northwestern University study.

8 Apr 2025